NF1 and neoplasm: The remaining patients that have neither gene mutation typically have de-regulated kinases including amplification and overexpression of PAK1 [6, 7], inactivation of the NF-1 tumor suppressor [8], loss of NF-1 associated with RAS activation [9, 10] and cell cycle aberrations such as CCND1 and CDK4 amplification [11].